atai Life Sciences to Participate in Upcoming February Investor Conference
atai Life Sciences N.V. (Nasdaq: ATAI) will participate in the Aegis Conference on February 24, 2022, at 11:30 a.m. ET. The conference will be virtual, and interested parties can access the presentation via this link.
Founded in 2018, atai focuses on innovative therapeutics for mental health disorders, including depression and anxiety. Their approach emphasizes psychedelics and drugs with unique safety profiles, aiming to expedite the development of effective treatments.
- None.
- None.
NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference in February.
Presentation details can be found below:
- Aegis Conference
Format: Virtual
Date and Time: Thursday, February 24, 2022, 11:30 a.m. ET
Webcast Link: https://bit.ly/3JuuKmV
The presentations and archived webcasts will also be accessible in the Events section of atai’s website.
About atai Life Sciences
atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.
atai's business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders.
atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. atai has offices in New York, London, and Berlin. For more information, please visit www.atai.life.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors discussed under the caption “Risk Factors” in atai's prospectus pursuant to Rule 424(b) filed with the U.S. Securities and Exchange Commission (“SEC”) on June 21, 2021, as such factors may be updated from time to time in atai's other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.
Contact Information
Investor Contact:
Chad Messer
VP, Investor Relations, atai Life Sciences
Email: chad@atai.life
Media Contact:
Camilla Dormer
VP, Communications, atai Life Sciences
Email: camilla@atai.life
FAQ
What conference is atai Life Sciences participating in February 2022?
What time is atai's presentation at the Aegis Conference?
Where can I watch the atai presentation from the Aegis Conference?
What is the mission of atai Life Sciences?
When was atai Life Sciences founded?
